Document is current
Any future updates will be listed below
-
Authors
Hamway, Youssef
Josten, Theresa
Abdellatif, Sherif
Mukherjee, Piyas
Schluckebier, Julia
Berry, Sèyigbéna P. Déo-Gracias
Honkpèhedji, Yabo Josiane
Maloum, Moustapha Nzamba
Laclong Lontchi, Romeo
Moure, Paul A. Nguema
Meulah, Brice
Hoekstra, Pytsje T.
Kroidl, Inge
van Dam, Govert J.
Kreidenweiss, Andrea
Esen, Meral
Adégnika, Ayôla Akim
Prazeres da Costa, Clarissa
-
Funding
Funding for this research was provided by:
European and Developing Countries Clinical Trials Partnership (RIA2016MC-1626-FREEBILY)
DFG (CO 1469/14-1)
Deutsches Zentrum für Infektionsforschung (TTU 03.818)
Technische Universität München
- License Information
-
More Information
Article History
Received: 18 December 2025
Accepted: 21 April 2026
First Online: 9 May 2026
Declarations
:
: The HelmVit study has been approved in Gabon by the institutional ethics committee of the Centre de Recherches Médicales de Lambaréné (CERMEL) (CEI-023/2018), in Germany by the university ethics committees of Munich (TUM) and Tübingen (UKT) (TUM 2016-349-S-KK; UKT 515/2017BO1). The study was registered on Clinical Trials.gov (Registration Number NCT04324853). All participants gave written informed consent. For pregnant minors, signed consent was obtained from their legal representative or guardians in addition to their assent. The study was conducted in line with the Good Clinical Practice (GCP) principles of the International Conference on Harmonization (ICH) and the Declaration of Helsinki.
: The authors declare no competing interests.
